Efficacy and tolerability of ziprasidone versus risperidone as augmentation in patients partially responsive to clozapine: a randomised controlled clinical trial

Journal of Psychopharmacology
Mathias ZinkHarald Dressing


Patients suffering from schizophrenic psychoses sometimes insufficiently respond to antipsychotic monotherapy and then combination approaches are preferred. We aimed in validating the add-on of ziprasidone and risperidone to clozapine, and we performed a randomised head-to-head trial. Patients with partial response to clozapine were randomly attributed to augmentation with ziprasidone (n = 12) or risperidone (n = 12). Efficacy assessments included the Positive and Negative Syndrome Scale (PANSS), the Scale for the Assessment of Negative Symptoms (SANS), the Hamilton Depression Scale (HAMD), the Clinical Global Impression (CGI) and the Global Assessment of Functioning (GAF). Furthermore, several safety and tolerability measures were obtained. After six weeks, both groups showed significant reductions of positive and negative symptoms. In addition, affective state, psychosocial functioning and clozapine side effects improved without significant differences between the groups. Both approaches were well tolerated. However, the ziprasidone group experienced a small elongation of the QTc interval and a reduction of extrapyramidal symptoms. Patients under clozapine-risperidone therapy developed a rise of serum prolactin levels. The cl...Continue Reading


Mar 31, 1998·The British Journal of Psychiatry : the Journal of Mental Science·R ShilohA Weizman
May 5, 2000·The Cochrane Database of Systematic Reviews·Kristian WahlbeckM A Essali
Apr 30, 2002·The Annals of Pharmacotherapy·Charles F Caley, Chandra K Cooper
Oct 9, 2002·Acta Psychiatrica Scandinavica·Stephen M Stahl
Oct 9, 2002·Acta Psychiatrica Scandinavica·Oliver Freudenreich, D C Goff
Feb 20, 2003·The Journal of Clinical Psychiatry·Michael P TwohigEllen J Teng
Mar 14, 2003·The Journal of Clinical Psychiatry·Neil S Kaye
May 21, 2003·The Journal of Clinical Psychiatry·Peter J WeidenRichard L O'Sullivan
Jun 26, 2003·The Journal of Clinical Psychiatry·Scott W Woods
Jul 5, 2003·The Annals of Pharmacotherapy·Jennifer E SchumacherHolly R Griffin
Nov 19, 2003·Journal of Clinical Psychopharmacology·Peter J WeidenSteven J Romano
Nov 25, 2003·The Journal of Clinical Psychiatry·Robert E McCueLeonel Urcuyo
Jan 8, 2004·Journal of Clinical Psychopharmacology·Edmund P HarriganMichelle Middle
Mar 5, 2004·The New England Journal of Medicine·Dan M Roden
Jun 8, 2004·Human Psychopharmacology·Mathias ZinkHarald Dressing
Jul 10, 2004·Psychiatrische Praxis·Mathias ZinkHarald Dressing
Oct 7, 2004·The American Journal of Psychiatry·Shari I LusskinJessica Jacobson
Dec 31, 2004·The American Journal of Psychiatry·Richard C JosiassenRita A Shaughnessy
Feb 25, 2005·Journal of Psychopharmacology·Elizabeth ToveyCallum Livingstone
Oct 22, 2005·Clinical Neuropharmacology·Marc ZiegenbeinHeike E Kuenzel
Jan 24, 2006·The Journal of Clinical Psychiatry·Georges M GharabawiAndrew Greenspan
Feb 3, 2006·The New England Journal of Medicine·W G HonerClozapine and Risperidone Enhancement (CARE) Study Group
Mar 7, 2006·Nature Reviews. Drug Discovery·T Scott StroupJ Lieberman
May 25, 2006·The Journal of Neuropsychiatry and Clinical Neurosciences·Marc Ziegenbein, Iris T Calliess
Dec 30, 2006·The Journal of Clinical Psychiatry·Berna Binnur Kivircik AkdedeHerbert Y Meltzer
Jan 12, 2007·Basic & Clinical Pharmacology & Toxicology·Edoardo Spina, Jose de Leon
Jan 1, 2003·Clinical Drug Investigation·Michael J ReinsteinLynne E Jones


Jun 2, 2012·Mens Sana Monographs·Susanne Englisch, Mathias Zink
Jul 10, 2014·ISRN Psychiatry·Natalia BartolommeiLorenzo Lattanzi
Mar 15, 2012·Current Psychiatry Reports·Rune Andreas Kroken, Erik Johnsen
Dec 18, 2010·Der Nervenarzt·Mathias ZinkAndreas Meyer-Lindenberg
Oct 7, 2014·Expert Opinion on Pharmacotherapy·Maria Rosaria MuscatelloRocco Zoccali
May 9, 2012·Expert Opinion on Drug Safety·Juan A GallegoChristoph U Correll
Sep 13, 2011·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Stefano PorcelliAlessandro Serretti
Dec 9, 2014·Expert Opinion on Drug Metabolism & Toxicology·Roberto MandrioliLaura Mercolini
Jan 25, 2011·Expert Opinion on Pharmacotherapy·Scott P Van Sant, Peter F Buckley
Jan 26, 2011·Schizophrenia Research·Maria Rosaria MuscatelloRocco Zoccali
Mar 31, 2012·General Hospital Psychiatry·Amaia López de TorreJuan Medrano
Jul 10, 2013·European Journal of Pharmacology·Andrea de BartolomeisCarmine Tomasetti
Jun 22, 2012·The International Journal of Neuropsychopharmacology·W Wolfgang Fleischhacker, Hiroyuki Uchida
Feb 9, 2017·Revista brasileira de psiquiatria : orgão oficial da Associação Brasileira de Psiquiatria, Asociación Psiquiátrica de la América Latina·Kerryn S Armstrong, Henk Temmingh
Jan 1, 2011·Journal of Central Nervous System Disease·Chiara MatteiStephen M Stahl
Jun 29, 2017·The Cochrane Database of Systematic Reviews·Javier Ortiz-OrendainClive E Adams
Jul 28, 2010·Expert Opinion on Pharmacotherapy·Andrea FagioliniAlessandro Rossi
Jan 7, 2010·Current Opinion in Psychiatry·Mathias ZinkAndreas Meyer-Lindenberg
Oct 23, 2013·Journal of Clinical Psychopharmacology·Maria Rosaria MuscatelloA Bruno
Jul 3, 2019·The International Journal of Neuropsychopharmacology·Sermin TotoAlexandra Neyazi
Oct 13, 2009·The Cochrane Database of Systematic Reviews·Katja KomossaStefan Leucht
Jul 16, 2015·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·Hiroyoshi TakeuchiHiroyuki Uchida
Mar 24, 2017·The Cochrane Database of Systematic Reviews·Sarah BarberAndrea Cipriani
May 8, 2018·The Australian and New Zealand Journal of Psychiatry·Dan SiskindSteve Kisely

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here


Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.